PreludeDx™ to Present DCISionRT® and Novel Resid

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...

Related Keywords

Australia , United States , Pat Whitworth , G Bruce Mann , Andrew Wade , Cory Dunn , Frank Vicini , Instagram , Linkedin , Prnewswire Prelude Corporation Preludedx , National Cancer Institute , Nashville Breast Center , American Society Of Breast Surgeons Asbr , Prelude Corporation , Facebook , University Of California San Francisco , Residual Risk Subtype , American Society , Breast Surgeons , Scientific Session Oral Presentations , Novel Residual Risk Subtype Identifies Patients , Varying Risk , Among Younger , High Grade , Nashville Breast , Friday April , Identifies Two Subsets , Significantly Different Risk , Local Recurrence , Novel Biologic Subtype Was Predictive , Elevated Recurrence Risk Despite , Prospective Registry Study , Clinical Utility , Treatment Decisions , Breast Conserving , Royal Women , California San Francisco , Know Your , Fjord Ventures , Decision Score , Know Your Risk , Preludedx ,